These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21059859)

  • 41. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
    Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
    Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
    Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
    Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
    Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
    Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
    Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
    Kanwal H; Khan MH; Rashid H
    Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
    Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
    Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A nucleoside diphosphate kinase A (nm23-H1) serine 120-->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction.
    Chang CL; Strahler JR; Thoraval DH; Qian MG; Hinderer R; Hanash SM
    Oncogene; 1996 Feb; 12(3):659-67. PubMed ID: 8637723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
    Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
    Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
    Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS
    Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of new ALK mutations at relapse of neuroblastoma.
    Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
    J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of ALK hotspot mutations in relapsed neuroblastoma.
    Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
    Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogenic mutations of ALK in neuroblastoma.
    Ogawa S; Takita J; Sanada M; Hayashi Y
    Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
    Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
    Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired.
    Serresi M; Piccinini G; Pierpaoli E; Fazioli F
    Oncogene; 2004 Feb; 23(5):1098-108. PubMed ID: 14691459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
    Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
    Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
    Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
    Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
    Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
    Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
    Huang H; Gont A; Kee L; Dries R; Pfeifer K; Sharma B; Debruyne DN; Harlow M; Sengupta S; Guan J; Yeung CM; Wang W; Hallberg B; Palmer RH; Irwin MS; George RE
    Cell Rep; 2021 Jul; 36(2):109363. PubMed ID: 34260934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
    Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
    Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.